Primary high-grade urothelial carcinoma of prostate with prostatic hyperplasia: a rare case report and review of the literature

References

• Shen SS, Lerner SP, Muezzinoglu B, et al. Prostatic involvement by transitional cell carcinoma in patients with bladder cancer and its prognostic significance. Hum Pathol. 2006;37(6):726–734. doi: 10.1016/j.humpath.2006.01.027.
   PubMed Web of Science ®Google Scholar
• Ende N, Woods LP, Shelley HS. Carcinoma originating in ducts surrounding the prostatic urethra. Am J Clin Pathol. 1963;40(2):183–189. doi: 10.1093/ajcp/40.2.183.
   PubMed Web of Science ®Google Scholar
• Kisa E, Semiz HS, Küçük Ü, et al. Metastatic primary urothelial carcinoma of the prostatic urethra: a case report. Urol J. 2019;86(3):161–164. doi: 10.1177/0391560318808631.
   Google Scholar
• Tan MO, Tuncel A, Deniz N, et al. Case report: incidental primary transitional cell carcinoma of the prostate treated with transurethral prostatectomy only. Tumori J. 2003;89(4):440–442. doi: 10.1177/030089160308900419.
   PubMed Web of Science ®Google Scholar
• Karpas CM, Moumgis B. Primary transitional cell carcinoma of prostate gland: possible pathogenesis and relationship to reserve cell hyperplasia of prostatic periurethral ducts. J Urol. 1969;101(2):201–205. doi: 10.1016/s0022-5347(17)62312-7.
   PubMed Web of Science ®Google Scholar
• Filter ER, Gabril MY, Gomez JA, et al. Incidental prostate adenocarcinoma in cystoprostatectomy specimens: partial versus complete prostate sampling. Int J Surg Pathol. 2017;25(5):414–420. doi: 10.1177/1066896917696745.
   PubMed Web of Science ®Google Scholar
• Sanguedolce F, Russo D, Mancini V, et al. Morphological and immunohistochemical biomarkers in distinguishing prostate carcinoma and urothelial carcinoma: a comprehensive review. Int J Surg Pathol. 2019;27(2):120–133. doi: 10.1177/1066896918814198.
   PubMed Web of Science ®Google Scholar
• Moschini M, Soria F, Susani M, et al. Impact of the level of urothelial carcinoma involvement of the prostate on survival after radical cystectomy. Bladder Cancer. 2017;3(3):161–169. doi: 10.3233/BLC-160086.
   PubMed Web of Science ®Google Scholar
• McKenney JK, Amin MB. The role of immunohistochemistry in the diagnosis of urinary bladder neoplasms. Semin Diagn Pathol. 2005;22(1):69–87. doi: 10.1053/j.semdp.2005.11.005.
   PubMed Web of Science ®Google Scholar
• Kunju LP, Mehra R, Snyder M, et al. Prostate-specific antigen, high-molecular-weight cytokeratin (clone 34betaE12), and/or p63: an optimal immunohistochemical panel to distinguish poorly differentiated prostate adenocarcinoma from urothelial carcinoma. Am J Clin Pathol. 2006;125(5):675–681. doi: 10.1309/V1RY-91NK-X5AR-W2Q5.
   PubMed Web of Science ®Google Scholar
• Chou J, Provot S, Werb Z. GATA3 in development and cancer differentiation: cells GATA have it!. J Cell Physiol. 2010;222(1):42–49. doi: 10.1002/jcp.21943.
   PubMed Web of Science ®Google Scholar
• Moschini M, Zamboni S, Mattei A, et al. Radical cystectomy in pathological T4a and T4b bladder cancer patients: is there any space for Sub stratification? Urol Int. 2019;102(3):269–276. doi: 10.1159/000493899.
   PubMed Web of Science ®Google Scholar
• Leissner J, Ghoneim MA, Abol-Enein H, et al. Extended radical lymphadenectomy in patients with urothelial bladder cancer: results of a prospective multicenter study. J Urol. 2004;171(1):139–144. doi: 10.1097/01.ju.0000102302.26806.fb.
   PubMed Web of Science ®Google Scholar
• Wu S, Lin SX, Lu M, et al. Assessment of 5-year overall survival in bladder cancer patients with incidental prostate cancer identified at radical cystoprostatectomy. Int Urol Nephrol. 2019;51(9):1527–1535. doi: 10.1007/s11255-019-02181-7.
   PubMed Web of Science ®Google Scholar
• Varinot J, Cussenot O, Roupret M, et al. HOXB13 is a sensitive and specific marker of prostate cells, useful in distinguishing between carcinomas of prostatic and urothelial origin. Virchows Arch. 2013;463(6):803–809. doi: 10.1007/s00428-013-1495-0.
   PubMed Web of Science ®Google Scholar
• Hardeman SW, Perry A, Soloway MS. Transitional cell carcinoma of the prostate following intravesical therapy for transitional cell carcinoma of the bladder. J Urol. 1988;140(2):289–292. doi: 10.1016/s0022-5347(17)41585-0.
   PubMed Web of Science ®Google Scholar
• Liedberg F, Chebil G, Månsson W. Urothelial carcinoma in the prostatic urethra and prostate: current controversies. Expert Rev Anticancer Ther. 2007;7(3):383–390. doi: 10.1586/14737140.7.3.383.
   PubMed Web of Science ®Google Scholar
• Bin Y, Guoliang W, Huiying H. Advances in pathology, diagnosis and treatment of nested variant urothelial carcinoma. Chin J Urol. 2017;38(2):155–157.
   Google Scholar
• Lin MC, Lin JJ, Hsu CL, et al. GATA3 interacts with and stabilizes HIF-1α to enhance cancer cell invasiveness. Oncogene. 2017;36(30):4243–4252. doi: 10.1038/onc.2017.8.
   PubMed Web of Science ®Google Scholar
• Oh WJ, Chung AM, Kim JS, et al. Differential immunohistochemical profiles for distinguishing prostate carcinoma and urothelial carcinoma. J Pathol Transl Med. 2016;50(5):345–354. doi: 10.4132/jptm.2016.06.14.
   PubMedGoogle Scholar
• Taylor JH, Davis J, Schellhammer P. Long-term follow-up of intravesical bacillus Calmette-Guérin treatment for superficial transitional-cell carcinoma of the bladder involving the prostatic urethra. Clin Genitourin Cancer. 2007;5(6):386–389. doi: 10.3816/CGC.2007.n.021.
   PubMed Web of Science ®Google Scholar
• Cui J, Wang W, Chen S, et al. Combination of intravesical chemotherapy and bacillus Calmette-Guerin versus bacillus Calmette-Guerin monotherapy in intermediate- and high-risk nonmuscle invasive bladder cancer: a systematic review and meta-analysis. Medicine (Baltimore). 2016;95(3):e2572. doi: 10.1097/MD.0000000000002572.
   PubMed Web of Science ®Google Scholar
• Hamasaki T, Kondo Y, Ogata Y, et al. Advanced carcinoma of the prostatic urethra in a patient with marked response to chemotherapy, leading to preservation of the bladder. Int J Clin Oncol. 2010;15(1):109–111. doi: 10.1007/s10147-009-0006-4.
   PubMed Web of Science ®Google Scholar
• Xing J, Zhang C, Liu Z, et al. Primary urothelial carcinoma of the prostate: a case report. Chin J Urol. 2019;40(2):148–148.
   Google Scholar
• Oliai BR, Kahane H, Epstein JI. A clinicopathologic analysis of urothelial carcinomas diagnosed on prostate needle biopsy. Am J Surg Pathol. 2001;25(6):794–801. doi: 10.1097/00000478-200106000-00012.
   PubMed Web of Science ®Google Scholar
• Lerner SP, Shen S. Pathologic assessment and clinical significance of prostatic involvement by transitional cell carcinoma and prostate cancer. Urol Oncol. 2008;26(5):481–485. doi: 10.1016/j.urolonc.2008.03.002.
   PubMed Web of Science ®Google Scholar
• Palou J, Baniel J, Klotz L, et al. Urothelial carcinoma of the prostate. Urology. 2007;69(1l):50–61. doi: 10.1016/j.urology.2006.05.059.
   PubMedGoogle Scholar